[Remimazolam-Update on basic pharmacologic principles and clinical potential]. / Remimazolam ­ Update zu Grundlagen und klinischem Potenzial.

ABSTRACT

In recent years the still relatively new short-acting benzodiazepine remimazolam has been approved and clinically implemented in several countries and regions. Remimazolam is also now approved in the EU and the market launch in Germany is expected in the not too distant future. This is therefore a good point in time to summarize the current evidence for various areas of application, including general anesthesia, sedation and intensive care medicine as well as different dosing schemes.